Medscape5d
Can Weight Loss Lead to Real Remission for Type 2 Diabetes?
Despite weight loss and glycemic control, experts caution that type 2 diabetes remission is not a cure and that pancreatic ...
Medscape7d
Automated Insulin Delivery System Helps in Type 2 Diabetes
The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...
BioSpace7d
GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors
The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...
Endocrinology Advisor8d
SGLT2 Inhibitor Use Not Linked to Postoperative Diabetic Ketoacidosis
SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.
Today's Dietitian9d
SGLT-2 Drug Plus Moderate Calorie Restriction Achieves Higher Diabetes Remission
Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...
Renal & Urology News12d
SGLT2 Inhibitors May Lower Stone Risk in Patients Regardless of Stone History
Compared with vs DPP4 inhibitors, SGLT2 inhibitors reduce the risk for kidney and ureteral stones in patients with type 2 diabetes, including those with a stone history. Sodium-glucose cotransporter 2 ...
AHA/ASA Journals13d
Myeloid Fatty Acid Metabolism Activates Neighboring Hematopoietic Stem Cells to Promote Heart Failure With Preserved Ejection Fraction
BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...
Daily13d
Updated chronic kidney disease management guidelines recommend SGLT2 inhibitors regardless of diabetes or kidney disease type
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are now recommended for persons with CKD with and without diabetes for both kidney and cardiovascular benefit. The guidelines also recommend statins ...
Endocrinology Advisor14d
SGLT2 Inhibitors May Reduce Hospitalization Rates in Myocardial Infarction
Compared with placebo, SGLT2 inhibitors reduced heart failure hospitalizations among patients with history of myocardial infarction. Sodium-glucose co-transporter 2 (SGLT2) inhibitors may ...
The Indian Express14d
Empagliflozin comes off patent, Indian manufacturers set to launch generic versions.
Affordability and access can bring down monthly drug bills of people with diabetes. Empagliflozin is the second in the class of medicines called SGLT-2 inhibitors to come off patent in India, the ...
The Financial Express14d
Boehringer Ingelheim’s blockbuster diabetes drug goes off patent today—Will it lower treatment costs in India?
Empagliflozin is the second in the class of medicines called SGLT-2 inhibitors to come off patent in India. Dapagliflozin was the first in this class whose patent expired in 2020. Leading domestic ...
thecardiologyadvisor.com15d
SGLT2 Inhibitors Confer Greater Cardioprotective Effect in Older Adults With T2D
SGLT2 inhibitors were associated with greater reduction in MACE risk among older adults than younger adults with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer a greater ...